11/4/2013 9:49:03 AM
Lund, Sweden, November 4, 2013 - Active Biotech (NASDAQ OMX NORDIC: ACTI)
announced today that its partner Teva Pharmaceutical Industries Ltd. (NYSE:
TEVA) will initiate a further clinical trial, LIBRETTO, to evaluate the
efficacy, safety and tolerability of two doses of oral laquinimod (0.6 and 1.2
mg/day), compared to interferon beta-1a, in patients with relapsing remitting
multiple sclerosis. Primary endpoint of the study will be brain atrophy. For
further details please see www.clinicaltrials.gov where the trial will appear
during this week.
Help employers find you! Check out all the jobs and post your resume.
comments powered by